Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MERTK | Q12866 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | TTR | P02766 | 1/20 | 0.35 |
| ▸ | PPOX | P50336 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL501648 | 0.85 | KCNQ3 (0.34) | MEN1KMT2AALDH1A1 | |
| SCHEMBL14674831 | 0.83 | TBXA2R (0.42) | MEN1KMT2ATDP1MAPT | |
| SCHEMBL14674130 | 0.83 | ALDH1A1 (0.43) | MERTKMEN1KMT2AMAPTMAOB | |
| SCHEMBL14674597 | 0.82 | LMNA (0.41) | MEN1KMT2AMAPTPOLBALDH1A1 | |
| SCHEMBL14674353 | 0.82 | AR (0.43) | — | |
| SCHEMBL14673681 | 0.81 | HTR2A (0.39) | MEN1KMT2ATDP1TTRPPOX | |
| SCHEMBL14674339 | 0.81 | AR (0.38) | MEN1KMT2ATDP1TTRPPOX | |
| SCHEMBL14674209 | 0.81 | MAPT (0.41) | MEN1KMT2AMAPTPOLBALDH1A1 | |
| SCHEMBL14675125 | 0.81 | EPAS1 (0.43) | MEN1KMT2ATDP1TTRPPOX | |
| SCHEMBL503056 | 0.81 | MAPT (0.38) | MEN1KMT2ATDP1MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946264-B2 | Pyridine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-02-03 | — | — | US | disclosed |
| US-20130045994-A1 | PYRIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-02-21 | — | — | US | disclosed |
| US-20120029026-A1 | PYRIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-02-02 | — | — | US | disclosed |
| EP-2404918-A1 | PYRIDINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2012-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029026-A1 | PYRIDINE DERIVATIVE | PPARD, PPARG, PPARA | MERTK 3234/4885MEN1 4140/4885KMT2A 3426/4885 |
| US-20130045994-A1 | PYRIDINE DERIVATIVE | PPARD, PPARG, PPARA | MERTK 3234/4885MEN1 4140/4885KMT2A 3426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.